Premium
Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease
Author(s) -
Gordon Alan N.,
Kavanagh John J.,
Gershenson David M.,
Saul Patton B.,
Copeland Larry J.,
Stringer G. Allen
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19861001)58:7<1407::aid-cncr2820580704>3.0.co;2-2
Subject(s) - medicine , vinblastine , methotrexate , combination chemotherapy , bleomycin , cisplatin , gestational trophoblastic disease , chemotherapy , vincristine , combination therapy , cyclophosphamide , gastroenterology , surgery , pregnancy , gestation , biology , genetics
Eleven patients were treated with cisplatin, vinblastine, and bleomycin (PVB) combination chemotherapy after failure of conventional triple‐agent therapy with methotrexate, dactinomycin, and cyclophosphamide for gestational trophoblastic disease. Often evaluable patients, five (50%) achieved negative titers. Sustained remission was achieved in only two patients (20%). Major hematologic toxicities and two deaths due to sepsis occurred in this group of patients. Although this combination does exhibit activity, its clinical use in the treatment of refractory trophoblastic disease is limited.